IPM Monthly Growth Drivers

AUG 2023 Dataset

Indian Pharma
Industry Performance
Presented by : Sheetal Sapale
Vice President - Commercial
Pharmarack

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Industry Mailer is property of. Any replication/publication without authorization would amount to legal action
 Content
01 IPM Therapy Performance

02 Growth Drivers

03 Growth Trend Analysis

04 Top 40 Corporates

05 Top 40 Brands

06 Key Takeaways

07 Opinions That Matter :

Patient Centricity
2
www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
IPM
IPMTherapy
MonthlyPerformance
Growth Drivers

The IPM has shown a growth of 5.1% in terms of Value and -3.1% in terms of Units for the month of August 23
Anti-neoplastics and Opthal / Otologicals are the only therapies that have shown a robust value as well as unit growth for the month of August 23

MAT AUG 23 MTH AUG 23

SUPER GROUP
Val Cr’s Val Contr% Val Gr% Unit Gr% Val Cr’s Val Contr% Val Gr% Unit Gr%
IPM 189130 100% 8.5% 0.9% 17095 100% 5.1% -3.1%
CARDIAC 24645 13% 8.6% 1.0% 2149 13% 5.1% -1.8%
ANTI-INFECTIVES 23530 12% 6.5% 2.0% 2210 13% 1.0% -3.7%
GASTROINTESTINAL 21936 12% 6.5% -0.6% 2060 12% 5.7% -1.5%
ANTI DIABETIC 17193 9% 5.0% 1.1% 1494 9% 4.5% -1.9%
V&M 16672 9% 7.5% -3.7% 1533 9% 4.8% -6.7%
RESPIRATORY 15786 8% 14.6% 8.5% 1298 8% -0.2% -6.5%
PAIN / ANALGESICS 13435 7% 9.7% -1.3% 1249 7% 6.3% -6.9%
DERMA 12627 7% 9.3% -1.3% 1137 7% 6.4% -1.3%
NEURO / CNS 11499 6% 7.4% -1.7% 1021 6% 5.0% -3.0%
GYNAECOLOGICAL 6378 3% 9.8% 2.1% 557 3% 4.0% -3.9%
BLOOD RELATED 5488 3% 8.6% -3.1% 522 3% 5.8% -6.3%
ANTI-NEOPLASTICS 4021 2% 17.8% 1.3% 392 2% 24.8% 14.4%
OPHTHAL / OTOLOG. 3454 2% 17.5% 12.1% 353 2% 33.2% 45.4%
HORMONES 3239 2% 9.9% 0.5% 289 2% 5.1% -2.0%
UROLOGY 2833 1% 9.2% 1.1% 248 1% 1.5% -4.3%
VACCINES 1677 1% -0.8% -3.3% 153 1% 7.6% -3.7%
OTHERS 1584 1% 3.6% 3.5% 147 1% 4.8% -1.9%
SEX STIM./ REJUV. 1349 1% 17.6% 9.0% 113 1% 7.6% 1.8%
Key findings:
STOMATOLOGICALS 1259 1% 19.3% 9.3% 114 1% 8.8% -0.5%
LoremMALARIALS
ANTI ipsum dolor sit amet, consectetur
525 adipiscing0%
elit. Integer eros ligula, feugiat eget
-2.5% dui quis, porttitor
-6.6% 57sagittis dui. Nulla
0% at auctor enim,
-1.1%eu volutpat -14.9%
velit.

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 IPM Monthly Growth Drivers

New Introductions and Price Increase have primarily driven the growth of the market for the month of Aug 23

IPM Monthly Growth Drivers

12.4 5 6.6 5.3 13.9 -0.2 -2 -4.8 -3.3 16.6 14.1 12.1 13 7.2 17.3 10.5 2.3 20.3 13.0 -1.0 5.6 6.0 5.3 5.1

Sep- Oct- Nov- Dec- Jan- Feb- Mar- Apr- May- Jun- Jul- Aug- Sep- Oct- Nov- Dec- Jan- Feb- Mar- Apr- May- Jun- Jul- Aug-
21 21 21 21 22 22 22 22 22 22 22 22 22 22 22 22 23 23 23 23 23 23 23 23
NP GR 1.3 1.4 1.2 1.4 2.8 2 0.9 -2.2 -1.7 1.1 1.5 1.5 1.9 1.8 2.2 2.2 1.8 2.8 2.9 2.5 3.0 3.1 3.1 3.3
Price GR 5.7 5.3 5.4 5.4 5.8 5.1 5.1 4.9 5 6.2 6.3 6.6 6.6 6.3 7.1 6.8 5.9 6.0 5.6 4.8 6.2 5.0 5.2 5.1
Vol GR 5.4 -1.6 0 -1.5 5.3 -7.3 -7.9 -7.5 -6.6 9.3 6.4 4 4.5 -0.9 8 1.4 -5.4 11.5 4.5 -8.2 -3.6 -2.1 -3.0 -3.3

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 IPM Monthly Growth Drivers

For the month of Aug 23, while most of the therapies have shown New Introductions and Price Increase
driven growth, in case of Anti-neoplastics and Opthal/Otologicals it is primarily Volume driven growth
AUG 23 MTH GROWTH DRIVERS

5.1 1.0 5.1 5.7 4.8 4.5 -0.2 6.3 6.4 5.0 4.0 5.8 24.8 33.2 5.1 1.5

VIT/MIN ANTI- PAIN/ NEURO / BLOOD ANTI- OPTH/ HORMO UROLOG

IPM ANTI-INF CARDIAC GASTRO RESPI DERMA GYNAEC
/NUTR DIAB ANAL CNS REL NEOP OTOL NES Y
NP GR 3.3 1.9 2.4 2.5 3.2 7.9 2.2 2.5 3.4 2.5 4.7 4.1 6.0 2.9 3.2 1.5
Price GR 5.1 2.0 4.0 6.9 7.9 4.3 7.9 6.4 5.1 5.5 3.5 4.8 -1.1 4.6 3.2 7.0
Vol GR -3.3 -3.0 -1.3 -3.7 -6.4 -7.7 -10.3 -2.7 -2.1 -3.1 -4.2 -3.1 19.9 25.8 -1.3 -7.0

AUG 23 MAT GROWTH DRIVERS

8.5 8.6 6.5 6.5 5.0 7.5 14.6 9.7 9.3 7.4 9.8 8.6 17.8 17.5 9.9 9.2

ANTI- ANTI- VIT/MIN PAIN/ NEURO / BLOOD ANTI- OPTH/ HORMO UROLOG
IPM CARDIAC GASTRO RESPI DERMA GYNAEC
INF DIAB /NUTR ANAL CNS REL NEOP OTOL NES Y
NP GR 2.4 1.7 1.3 1.4 6.7 2.3 2.1 1.9 2.4 2.1 4.0 2.6 3.3 2.4 1.8 1.1
Price GR 5.7 5.4 4.2 7.3 1.2 7.4 8.7 6.9 6.3 6.1 4.6 6.4 0.6 6.0 5.4 6.8
Vol GR 0.4 1.6 1.1 -2.2 -3.0 -2.2 3.8 0.8 0.5 -0.8 1.1 -0.4 13.9 9.1 2.7 1.4

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 Growth TrendGrowth
IPM Monthly Analysis
Drivers

A comparative analysis of Mth growths over last 4 year vs consumption patterns analysis using
MAT and MTH multiplier over Aug 19 consumption
MAT UNIT MULTIPLIER OVER MTH UNIT MULTIPLIER OVER
MTH VAL GR MTH UNIT GR%
SUPER GROUP AUG 19 AUG 19
Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23
IPM -2% 18% 12% 5% -9% 11% 5% -3% 0.98 1.04 1.04 1.05 0.91 1.01 1.06 1.03
CARDIAC 12% 7% 15% 5% 2% 1% 5% -2% 1.03 1.06 1.04 1.05 1.02 1.03 1.08 1.06
ANTI-INFECTIVES -11% 29% 2% 1% -21% 23% 1% -4% 0.94 0.98 1.00 1.02 0.79 0.97 0.99 0.95
GASTRO -2% 23% 14% 6% -9% 11% 8% -2% 0.95 1.08 1.07 1.07 0.91 1.01 1.09 1.07
ANTI DIABETIC 2% 10% 8% 4% 0% 3% 5% -2% 1.03 1.06 1.07 1.08 1.00 1.03 1.08 1.06
VIT / MIN / NUTR 6% 11% 11% 5% 3% -4% 2% -7% 0.98 1.10 0.99 0.95 1.03 0.99 1.01 0.94
RESPIRATORY -12%
Sample Multiplier 39% Approach
Calculation 19% 0% -20% 28% 14% -6% 1.00 0.97 1.07 1.16 0.80 1.02 1.16 1.09
PAIN / ANALGESICS -7% 33% 10% 6% -12%MAT UNITS
24% 0001% -7% 0.97 1.09 1.12 1.10 0.88 1.09 1.11 1.03
DERMA 0%
Aug-19 12% Aug-20
14% 6% -2%
Aug-21-6% 4% Aug-22
-1% 0.97 0.98
Aug-23 0.94 0.93 0.98 0.93 0.96 0.95
NEURO / CNS 0% 15% 15% 5% -4% 6% 4% -3% 1.00 1.02 1.04 1.02 0.96 1.02 1.06 1.03
IPM 22806823 22318440 23710396 23778176 23994628
GYNAECOLOGICAL -9% 27% 22% 4% -6% 22% 10% -4% 0.97 1.08 1.20 1.23 0.94 1.14 1.25 1.20
BLOOD Calculation
RELATED 0% 22318440/22806823
14% 17% 6% 23710396/22806823
-9% 4% 23778176/22806823
4% -6% 0.9623994628/22806823
0.98 0.97 0.94 0.91 0.95 0.98 0.92
Multiplier
ANTI-NEOPLASTICS -1% 2% 0.98
27% 25% 17%1.04 -5% 2% 1.04
14% 1.12 1.05 1.22
1.19 1.23 1.17 1.12 1.14 1.31
OPHTHAL / OTOL -13% 22% 14% 33% -16% 8% 6% 45% 0.91 0.87 0.91 1.02 0.84 0.91 0.96 1.40
HORMONES -2% 15% 13% 5% -12% 11% 2% -2% 0.94 1.01 0.97 0.98 0.88 0.97 0.99 0.97
UROLOGY 10% 12% 21% 2% -4% 9% 12% -4% 0.98 1.06 1.12 1.14 0.96 1.05 1.17 1.12
VACCINES -7% -7% -11% 8% 19% -14% -5% -4% 1.29 1.30 1.18 1.15 1.19 1.02 0.97 0.93
OTHERS -4% 22% 14% 5% 0% 24% 12% -2% 1.03 1.09 1.31 1.36 1.00 1.24 1.39 1.36
SEX STIM / REJUV -12% 35% 35% 8% -13% 25% 17% 2% 0.94 1.01 1.24 1.35 0.87 1.09 1.27 1.30
STOMATOLOGICALS 13% 13% 22% 9% 2% 5% 13% -1% 1.00 1.08 1.10 1.20 1.02 1.06 1.20 1.19
ANTI MALARIALS -5% 14% -17% -1% -14% 25% -24% -15% 1.07 1.11 0.95 0.88 0.86 1.08 0.82 0.69

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 Growth TrendGrowth
IPM Monthly Analysis
Drivers

A comparative analysis of Mth growths over last 4 year vs consumption patterns analysis using
MAT and MTH multiplier over Aug 19 consumption
MAT UNIT MULTIPLIER OVER MTH UNIT MULTIPLIER OVER
MTH VAL GR MTH UNIT GR%
SUPER GROUP AUG 19 AUG 19
Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23
IPM -2% 18% 12% 5% -9% 11% 5% -3% 0.98 1.04 1.04 1.05 0.91 1.01 1.06 1.03
CARDIAC 12% 7% 15% 5% 2% 1% 5% -2% 1.03 1.06 1.04 1.05 1.02 1.03 1.08 1.06
ANTI-INFECTIVES -11% 29% 2% 1% -21% 23% 1% -4% 0.94 0.98 1.00 1.02 0.79 0.97 0.99 0.95
GASTRO -2% 23% 14% 6% -9% 11% 8% -2% 0.95 1.08 1.07 1.07 0.91 1.01 1.09 1.07
ANTI DIABETIC 2% 10% 8% 4% 0% 3% 5% -2% 1.03 1.06 1.07 1.08 1.00 1.03 1.08 1.06
VIT / MIN / NUTR 6% 11% 11% 5% 3% -4% 2% -7% 0.98 1.10 0.99 0.95 1.03 0.99 1.01 0.94
RESPIRATORY -12% 39% 19% 0% -20% 28% 14% -6% 1.00 0.97 1.07 1.16 0.80 1.02 1.16 1.09
PAIN / ANALGESICS -7% 33% 10% 6% -12% 24% 1% -7% 0.97 1.09 1.12 1.10 0.88 1.09 1.11 1.03
DERMA 0% 12% 14% 6% -2% -6% 4% -1% 0.97 0.98 0.94 0.93 0.98 0.93 0.96 0.95
NEURO / CNS 0% 15% 15% 5% -4% 6% 4% -3% 1.00 1.02 1.04 1.02 0.96 1.02 1.06 1.03
GYNAECOLOGICAL -9% 27% 22% 4% -6% 22% 10% -4% 0.97 1.08 1.20 1.23 0.94 1.14 1.25 1.20
BLOOD RELATED 0% 14% 17% 6% -9% 4% 4% -6% 0.96 0.98 0.97 0.94 0.91 0.95 0.98 0.92
ANTI-NEOPLASTICS -1% 2% 27% 25% 17% -5% 2% 14% 1.12 1.19 1.22 1.23 1.17 1.12 1.14 1.31
OPHTHAL / OTOL -13% 22% 14% 33% -16% 8% 6% 45% 0.91 0.87 0.91 1.02 0.84 0.91 0.96 1.40
HORMONES -2% 15% 13% 5% -12% 11% 2% -2% 0.94 1.01 0.97 0.98 0.88 0.97 0.99 0.97
UROLOGY 10% 12% 21% 2% -4% 9% 12% -4% 0.98 1.06 1.12 1.14 0.96 1.05 1.17 1.12
VACCINES -7% -7% -11% 8% 19% -14% -5% -4% 1.29 1.30 1.18 1.15 1.19 1.02 0.97 0.93
OTHERS -4% 22% 14% 5% 0% 24% 12% -2% 1.03 1.09 1.31 1.36 1.00 1.24 1.39 1.36
SEX STIM / REJUV -12% 35% 35% 8% -13% 25% 17% 2% 0.94 1.01 1.24 1.35 0.87 1.09 1.27 1.30
STOMATOLOGICALS 13% 13% 22% 9% 2% 5% 13% -1% 1.00 1.08 1.10 1.20 1.02 1.06 1.20 1.19
ANTI MALARIALS -5% 14% -17% -1% -14% 25% -24% -15% 1.07 1.11 0.95 0.88 0.86 1.08 0.82 0.69

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 Growth TrendGrowth
IPM Monthly Analysis
Drivers

CARDIAC THERAPY

MAT UNIT MULTIPLIER OVER MTH UNIT MULTIPLIER OVER

MTH VAL GR MTH UNIT GR%
SUPER GROUP AUG 19 AUG 19
Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23
CARDIAC 12% 7% 15% 5% 2% 1% 5% -2% 1.03 1.06 1.04 1.05 1.02 1.03 1.08 1.06
ANTI- -
9% 5% 14% 3% 3% -2% 4% -3% 3 1.04 1.04 1.01 1.01 1.03 1.00 1.04 1.02
HYPERTENSIVES %

LIPID LOWERING 1
7% 18% 21% 7% -1% 9% 11% 1% % 1.03 1.08 1.14 1.19 0.99 1.08 1.19 1.20
DRUGS
PLATELET
1
AGGREGATION -4% 10% 23% 7% 1% 9% 3% 1% % 1.03 1.11 1.08 1.10 1.01 1.10 1.13 1.14
INHIBITORS
-
ANTI-ANGINALS 5% 6% 18% 7% -3% -4% 6% -6% 6 0.96 0.95 0.93 0.92 0.97 0.93 0.99 0.93
%
-
DIURETICS 11% 13% 18% 9% 2% 3% 6% -3% 3 1.02 1.08 1.08 1.08 1.02 1.05 1.11 1.07
%
1
HEPARINS 122% -25% -18% 17% 84% -25% -18% 12% 2 1.06 1.84 1.08 1.10 1.84 1.37 1.12 1.25
%
1
CARDIAC THERAPY 35% 21% 7% 0% 18% 71% 4% 12% 2 1.05 2.08 2.02 2.26 1.18 2.03 2.10 2.35
%

HEART FAILURE -
8% 16% 22% 0% -3% 9% 14% -8% 8 1.01 1.09 1.12 1.12 0.97 1.06 1.21 1.12
THERAPIES %

OTHER
2
CARDIOVASCULAR -8% 32% 28% 18% -5% 16% 15% 2% % 1.01 1.18 1.30 1.36 0.95 1.10 1.27 1.30
PRODUCTS
-
1
FIBRINOLYTICS 1% 13% 45% -16% -11% 31% -10% -16% 6 0.91 1.22 1.04 0.97 0.89 1.17 1.06 0.89
%

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 Growth TrendGrowth
IPM Monthly Analysis
Drivers

ANTI-INFECTIVES THERAPY

MAT UNIT MULTIPLIER OVER MTH UNIT MULTIPLIER OVER

MTH VAL GR MTH UNIT GR%
SUPER GROUP AUG 19 AUG 19
Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23
ANTI-
-11% 29% 2% 1% -21% 23% 1% -4% 0.94 0.98 1.00 1.02 0.79 0.97 0.99 0.95
INFECTIVES
ANTI-BACTERIALS -19% 41% 7% 1% -24% 30% 2% -4% 0.94 0.99 1.03 1.06 0.76 0.99 1.01 0.97
ANTI-FUNGAL -13% 20% -16% 5% -18% -14% 2% -8% 0.92 0.78 0.71 0.68 0.82 0.71 0.72 0.66
ANTI-VIRALS 84% -30% -28% 0% 41% -13% -2% 9% 1.00 1.68 1.04 1.19 1.41 1.22 1.19 1.30

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 Growth TrendGrowth
IPM Monthly Analysis
Drivers

RESPIRATORY THERAPY

MAT UNIT MULTIPLIER OVER MTH UNIT MULTIPLIER OVER

MTH VAL GR MTH UNIT GR%
SUPER GROUP AUG 19 AUG 19
Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23 Aug-20 Aug-21 Aug-22 Aug-23
RESPIRATORY -12% 39% 19% 0% -20% 28% 14% -6% 1.00 0.97 1.07 1.16 0.80 1.02 1.16 1.09
ANTI-ASTHMA AND
-8% 34% 23% 3% -22% 31% 20% -3% 1.00 0.95 1.08 1.24 0.78 1.03 1.23 1.19
COPD PRODUCTS
COUGH & COLD
-21% 52% 18% -8% -27% 43% 8% -16% 1.01 0.95 1.07 1.10 0.73 1.04 1.12 0.94
MKT
SYSTEMIC
-12% 15% 18% 0% -7% -1% 7% -7% 1.01 0.99 0.97 0.91 0.93 0.93 0.99 0.92
ANTIHISTAMINES
NASAL
-2% 33% 17% 5% -10% 35% 8% 2% 0.98 1.10 1.22 1.30 0.90 1.21 1.30 1.33
PREPARATION
OTHER
RESPIRATORY 39% 209% -56% 18% 12% 89% -47% -16% 0.98 1.91 1.16 0.95 1.12 2.12 1.13 0.94
SYSTEM PRODUCTS

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 Growth TrendGrowth
IPM Monthly Analysis
Drivers

Likely Reasons for the Growth Trends

• Small local players becoming more aggressive in Acute Segments having ease of
manufacturing

• Online pharmacies gaining popularity for Chronic Segments, especially where the
patient needs to be on the drug for lifetime

• Generics stores (Dawa India, Jan Aushadhi) seeing increase in footfalls

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 IPM Monthly Growth Drivers

Top 40 Corporates

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 Top
IPM1-20 Corporates
Monthly Growth Drivers

A few key corporates continue to show a positive unit growth despite the market challenges for the month of Aug 23

MAT AUG 23 MTH AUG 23

CORPORATE MAT VAL MAT UNIT MTH VAL MTH UNIT
MAT VAL RANK CONT% SALES VAL RANK CONT%
GR% GR% GR% GR%
IPM 189130 100% 8.5% 0.9% 17095 100% 5.1% -3.1%
SUN* 15817 1 8.4% 6.7% 0.8% 1460 1 8.5% 9.5% 1.9%
ABBOTT* 12074 2 6.4% 12.1% 2.4% 1082 2 6.3% 7.0% -4.1%
MANKIND 9801 3 5.2% 13.6% 6.5% 913 3 5.3% 10.0% 1.0%
CIPLA 9542 4 5.0% 10.4% 13.2% 837 4 4.9% 4.2% 3.3%
ZYDUS* 7300 5 3.9% 6.5% -3.8% 665 5 3.9% 6.9% -7.2%
TORRENT 6855 6 3.6% 11.6% 0.3% 617 7 3.6% 8.5% -1.7%
ALKEM* 6574 7 3.5% 9.6% 2.9% 621 6 3.6% 4.4% 1.8%
LUPIN 6436 8 3.4% 5.3% -0.5% 566 10 3.3% 4.4% -1.8%
INTAS 6363 9 3.4% 11.9% 1.0% 572 8 3.3% 6.1% -6.1%
MACLEODS 6149 10 3.3% 12.8% 4.7% 571 9 3.3% 8.4% -0.3%
ARISTO 5553 11 2.9% 10.9% 1.1% 504 11 3.0% 4.0% -6.0%
DR. REDDYS 5487 12 2.9% 7.6% 0.4% 486 12 2.8% 4.7% -0.7%
EMCURE* 5290 13 2.8% 7.3% 2.0% 475 13 2.8% 0.4% -6.9%
GSK 4886 14 2.6% 6.6% 0.0% 447 14 2.6% 2.2% -1.5%
USV 3899 15 2.1% 9.8% 2.3% 350 16 2.0% 8.1% 3.2%
GLENMARK 3853 16 2.0% 11.3% 7.0% 357 15 2.1% 6.0% -2.1%
IPCA 3531 17 1.9% 3.2% -6.3% 330 17 1.9% 2.5% -8.7%
PFIZER* 3469 18 1.8% -6.0% -11.2% 272 20 1.6% -13.1% -11.1%
MICRO 3213 19 1.7% 6.8% -7.8% 293 18 1.7% 3.2% -17.0%
SANOFI INDIA 3130 20 1.7% -3.8% -6.0% 288 19 1.7% -0.3% -2.6%

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 Top
IPM21-40 Corporates
Monthly Growth Drivers

A few key corporates continue to show a positive unit growth despite the market challenges for the month of Aug 23

MAT AUG 23 MTH AUG 23

CORPORATE MAT VAL MAT UNIT MTH VAL MTH UNIT
MAT VAL RANK CONT% SALES VAL RANK CONT%
GR% GR% GR% GR%
IPM 189130 100% 8.5% 0.9% 17095 100% 5.1% -3.1%
ERIS LS 2351 21 1.2% 10.5% -1.1% 203 21 1.2% 1.7% -11.3%
ALEMBIC 2135 22 1.1% 9.8% 2.1% 192 22 1.1% 3.1% -5.5%
FDC 1573 23 0.8% 9.9% 4.4% 149 23 0.9% 1.1% 0.6%
CADILA 1405 24 0.7% 2.2% -9.3% 131 24 0.8% 1.4% 4.1%
HIMALAYA 1348 25 0.7% -1.4% -12.5% 121 26 0.7% 1.7% -13.4%
LA RENON 1346 26 0.7% 19.5% 11.5% 125 25 0.7% 13.6% 3.4%
AJANTA 1313 27 0.7% 8.5% 2.9% 114 29 0.7% 5.7% 3.8%
JB CHEMICALS 1293 28 0.7% 6.0% -6.5% 120 27 0.7% 6.1% -12.6%
INDOCO 1255 29 0.7% 7.6% -1.5% 120 28 0.7% 5.3% -4.0%
FRANCO 1161 30 0.6% 8.3% -1.2% 106 31 0.6% 2.8% -7.3%
HETERO 1124 31 0.6% 12.8% 1.4% 106 30 0.6% 9.3% -12.0%
HEGDE & HEGDE 1063 32 0.6% 7.5% 4.5% 95 33 0.6% 4.4% 2.0%
CORONA 1031 33 0.5% 10.4% 2.5% 100 32 0.6% 16.6% 8.9%
BLUE CROSS 1024 34 0.5% 0.4% -6.4% 91 35 0.5% -10.3% -14.0%
BHARAT SERUMS 1015 35 0.5% -2.2% -4.2% 93 34 0.5% 10.5% -0.5%
MEDLEY 970 36 0.5% 5.9% -3.9% 91 36 0.5% -1.1% -9.4%
APEX 941 37 0.5% 9.5% 6.4% 87 37 0.5% -2.0% -3.8%
FOURRTS 902 38 0.5% 7.1% 2.4% 80 39 0.5% 3.8% -1.8%
SYSTOPIC 897 39 0.5% 9.4% -1.4% 84 38 0.5% 8.9% -0.9%
WALLACE* 845 40 0.4% 9.5% -1.6% 80 40 0.5% 3.4% -7.5%

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 IPM Monthly Growth Drivers

TOP 40 BRANDS

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 Top
IPM1-20 brands
Monthly Growth Drivers

Augmentin stands at no. 1 position with robust unit growth for the month of Aug 23
Pan, Volini and Manforce show a robust double digit growth for the month of Aug 23
MAT AUG 23 MTH AUG 23
CORPORATE BRANDS
MAT VA MAT UNIT MTH VAL MTH UNIT
MAT VAL RANK SALES VAL RANK
GR% GR% GR% GR%
GSK AUGMENTIN 786 1 15.6% 14.1% 76 1 2.3% 7.0%
USV GLYCOMET GP 766 2 9.9% 3.4% 65 2 1.4% -3.5%
MANKIND MANFORCE 677 3 29.5% 24.2% 58 3 13.0% 13.6%
CIPLA FORACORT 589 4 23.5% 20.5% 50 6 8.1% 4.7%
ABBOTT* MIXTARD 576 5 -3.7% -12.1% 47 7 -9.8% -20.7%
WIN-MEDICARE BETADINE 503 6 9.7% 0.1% 46 8 -4.8% -8.3%
HIMALAYA LIV.52 492 7 -2.8% -16.0% 52 4 20.0% 0.4%
SUN* ROSUVAS 487 8 11.4% 6.0% 45 9 12.4% 9.2%
ABBOTT* THYRONORM 481 9 7.9% 4.1% 42 13 1.7% 2.6%
ABBOTT* UDILIV 480 10 4.3% -5.3% 44 11 5.7% -3.6%
ARISTO MONOCEF 474 11 -2.9% -8.7% 51 5 2.3% -1.8%
SANOFI INDIA LANTUS 466 12 -15.2% -11.7% 33 23 -27.2% -9.0%
IPCA ZERODOL SP 452 13 7.2% -1.6% 40 14 3.9% -5.5%
ALKEM* PAN 450 14 9.9% 5.4% 43 12 19.1% 11.1%
GSK CALPOL 429 15 12.0% 3.5% 44 10 5.5% -0.4%
EMCURE* OROFER-XT 424 16 14.9% 4.2% 37 16 0.5% -9.7%
CIPLA BUDECORT 409 17 30.8% 25.9% 30 31 -4.2% 1.3%
SUN* VOLINI 398 18 8.2% 3.3% 38 15 8.7% 10.3%
ALKEM* CLAVAM 394 19 5.6% 4.8% 35 18 -1.5% -0.1%
APEX ZINCOVIT 391 20 -2.8% -5.2% 34 22 -17.0% -16.8%

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 Top
IPM21-40 brandsGrowth Drivers
Monthly

Ryzodeg, T-Bact and Telma show a phenomenal double digit unit growth for the month of Aug 23

MAT AUG 23 MTH AUG 23

CORPORATE BRANDS
MAT VA MAT UNIT MTH VAL MTH UNIT
MAT VAL RANK SALES VAL RANK
GR% GR% GR% GR%
ABBOTT*(NOVO) RYZODEG 381 21 48.3% 40.9% 35 19 34.8% 35.5%
CIPLA DUOLIN 380 22 15.8% 11.6% 29 32 -5.1% -11.2%
ALKEM* PAN D 370 23 7.6% 1.7% 33 24 5.9% 0.3%
MSD* JANUMET 366 24 -20.8% -10.5% 25 43 -30.1% -30.2%
JANSSEN ULTRACET 365 25 2.8% -6.1% 34 20 13.4% 4.0%
GSK T BACT 363 26 16.3% 10.4% 34 21 3.2% 18.4%
USV ECOSPRIN AV 360 27 22.2% 9.9% 32 29 10.9% 5.5%
ARISTO PANTOP 356 28 9.7% 3.8% 33 26 4.7% 2.2%
MICRO DOLO 349 29 -13.4% -18.1% 27 36 -32.6% -36.9%
CADILA ACILOC 343 30 -12.2% -13.0% 35 17 -0.9% 4.1%
SUN* LEVIPIL 335 31 3.1% -14.7% 32 28 10.7% -9.9%
GLENMARK TELMA 333 32 12.7% 15.1% 31 30 3.8% 18.3%
ARISTO MIKACIN 325 33 5.6% 1.5% 32 27 2.4% -3.3%
PFIZER* BECOSULES 324 34 -1.5% -9.5% 26 40 -12.0% -13.6%
FRANCO DEXORANGE 323 35 7.5% -2.1% 33 25 11.6% 1.5%
MANKIND PREGA NEWS 322 36 27.6% 17.8% 27 34 4.3% -4.4%
ABBOTT* NOVOMIX 319 37 -6.8% -13.9% 25 47 -15.2% -22.3%
MANKIND MOXIKIND CV 311 38 12.9% 1.7% 27 37 -4.7% -19.3%
TORRENT SHELCAL 301 39 3.7% -6.9% 26 41 -2.8% -11.5%
FDC ELECTRAL 295 40 17.4% 7.9% 26 39 8.5% 2.4%

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 Top
IPM21-40 brandsGrowth Drivers
Monthly

Key Takeaways
• The IPM has shown a growth of 5.1% in terms of Value and -3.1% in terms of Units for the month of August 23.
Growth for the market is primarily New Introduction and Price Driven for majority of the segments.
• Anti-neoplastics and Opthal / Othologicals are the only therapies that have shown a robust value as well as unit
growth for the month of August 23. These two categories have shown a strong volume driven growth

• Likely Reasons for the Growth Trends

• Small local players becoming aggressive in Acute segments
• Online pharmacies gaining popularity in Chronic segments
• Generic stores ( Dawa India, Jan Aushadhi, etc) gaining footfalls

• Despite the growth challenges

• Among the top 40 Corporates Sun, Mankind, USV, Cipla, FDC, Cadila, La Renon, Ajanta, Hegde & Hegde
and Corona show Unit growth for the month of Aug 23
• Among the top 40 Brands
• Augmentin stands at No 1 position for MAT and MTH Aug 23.
• Brands like Pan, Volini, Ryzodeg, T Bact and Telma show a double digit Unit growth for the month of
Aug 23

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 IPM Monthly Growth Drivers

Opinions That Matter

TOPIC

Patient Centricity
Speaker: Mr. Brijendra Singh
Vertical Head, Sr. Vice president- Sales & Mktg

Company: Lupin Ltd

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action
 IPM Monthly Growth Drivers

For any further

detail you can
connect with us on
pharmatracsupport@aiocdawacs.com

www.pharmarack.com Source: PHARMATRAC MAT AUG 2023 VAL IN CR ; UNITS IN 000 | The Content of this Webinar is property of. Any replication/publication without authorization would amount to legal action